246 related articles for article (PubMed ID: 19860732)
1. Purine-scaffold Hsp90 inhibitors.
Taldone T; Chiosis G
Curr Top Med Chem; 2009; 9(15):1436-46. PubMed ID: 19860732
[TBL] [Abstract][Full Text] [Related]
2. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
3. Development of purine-scaffold small molecule inhibitors of Hsp90.
Chiosis G; Lucas B; Huezo H; Solit D; Basso A; Rosen N
Curr Cancer Drug Targets; 2003 Oct; 3(5):371-6. PubMed ID: 14529388
[TBL] [Abstract][Full Text] [Related]
4. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.
Patel PD; Yan P; Seidler PM; Patel HJ; Sun W; Yang C; Que NS; Taldone T; Finotti P; Stephani RA; Gewirth DT; Chiosis G
Nat Chem Biol; 2013 Nov; 9(11):677-84. PubMed ID: 23995768
[TBL] [Abstract][Full Text] [Related]
5. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
6. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of purine-scaffold Hsp90 inhibitors.
Chiosis G
Curr Top Med Chem; 2006; 6(11):1183-91. PubMed ID: 16842155
[TBL] [Abstract][Full Text] [Related]
8. Structure-based and in silico design of Hsp90 inhibitors.
Sgobba M; Rastelli G
ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
[TBL] [Abstract][Full Text] [Related]
11. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.
Chiosis G; Lucas B; Shtil A; Huezo H; Rosen N
Bioorg Med Chem; 2002 Nov; 10(11):3555-64. PubMed ID: 12213470
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
13. The Hsp90 chaperone machinery: from structure to drug development.
Hahn JS
BMB Rep; 2009 Oct; 42(10):623-30. PubMed ID: 19874705
[TBL] [Abstract][Full Text] [Related]
14. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
15. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design.
Verkhivker GM; Dixit A; Morra G; Colombo G
Curr Top Med Chem; 2009; 9(15):1369-85. PubMed ID: 19860735
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of hsp90 inhibitors as anti-cancer drugs.
Xiao L; Lu X; Ruden DM
Mini Rev Med Chem; 2006 Oct; 6(10):1137-43. PubMed ID: 17073714
[TBL] [Abstract][Full Text] [Related]
17. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
18. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
19. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
20. Orally active purine-based inhibitors of the heat shock protein 90.
Biamonte MA; Shi J; Hong K; Hurst DC; Zhang L; Fan J; Busch DJ; Karjian PL; Maldonado AA; Sensintaffar JL; Yang YC; Kamal A; Lough RE; Lundgren K; Burrows FJ; Timony GA; Boehm MF; Kasibhatla SR
J Med Chem; 2006 Jan; 49(2):817-28. PubMed ID: 16420067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]